The Relative Strength (RS) Rating for Eli Lilly climbed into a higher percentile Tuesday, as it got a lift from 67 to 71.
IBD's proprietary RS Rating measures market leadership by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database.
Over 100 years of market history reveals that the market's biggest winners tend to have an RS Rating north of 80 as they launch their biggest price moves. See if Eli Lilly can continue to rebound and clear that threshold.
Can You Really Time The Stock Market?
Eli Lilly is trying to complete a cup with handle with a 935.63 buy point. See if the stock can break out in heavy trade.
Earnings growth declined last quarter from 1,080% to 114%, but sales rose from 20% to 45%.
The company holds the No. 2 rank among its peers in the Medical-Diversified industry group. AstraZeneca ADR is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
